首页|期刊导航|中国食品药品监管|生物制品批签发"AI技术+数字化平台"应用研究

生物制品批签发"AI技术+数字化平台"应用研究OA

Application Research of AI Technology and Digital Platforms in Batch Certification of Biologics

中文摘要英文摘要

目的:破解生物制品传统批签发模式痛点,提升监管效率与风险防控能力,推动药品智慧监管落地.方法:以人工智能(AI)技术与数字化平台为核心,构建涵盖数据建模、实时采集、在线审批等九大模块的总体架构,围绕智能问答、数据清洗、自动报告、风险预警四大场景开展应用研究,并结合实践进行验证.结果:形成了完整技术方案与应用体系,实践试点后批签发审核周期缩短 70%、审核准确率达 97%、协同效率提升 60%,能够有效识别异常数据与质量风险.结论:"AI技术+数字化平台"可显著优化批签发全流程,为生物制品全生命周期智能监管提供可复制经验,是药品监管现代化的重要路径.

Objective:This study aims to address the pain points of the traditional batch release model for biological products,improve regulatory efficiency and risk prevention and control capabilities,and promote the implementation of intelligent drug regulation.Methods:Taking AI technology and a digital platform as the core,a general architecture covering nine modules,including data modeling,real-time data collection,and online approval,was constructed.Application research was conducted in four scenarios:intelligent Q&A,data cleaning,automatic report generation,and risk early warning,and was validated through practical application.Results:A complete technical solution and application system were established.After the pilot implementation,the batch release review cycle was shortened by 70%,the review accuracy rate reached 97%,and collaboration efficiency increased by 60%.The system was able to effectively identify abnormal data and quality risks.Conclusion:The"AI technology+digital platform"approach can significantly optimize the entire batch release process,provide replicable experience for intelligent regulation throughout the lifecycle of biological products,and serve as an important pathway for the modernization of drug regulation.

徐鹤;孟庆妍;邹墅;高雅松;赵海峰

吉林省药品检验研究院吉林省药品检验研究院吉林省药品检验研究院吉林省药品检验研究院吉林省药品检验研究院

医药卫生

生物制品批签发人工智能数字化平台智慧监管数据安全风险预警

biological productsbatch releaseartificial intelligencedigital platformintelligent supervisiondata securityrisk early warning

《中国食品药品监管》 2026 (9)

104-111,8

2025年中国药品监管研究会课题(2025-Y-Y-024)

10.3969/j.issn.1673-5390.2026.09.010

评论